ALXN:NSD-Alexion Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 182.50

Change

0.00 (0.00)%

Market Cap

USD 40.34B

Volume

3.00

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Alexion Pharmaceuticals Inc (ALXN) Stock Analysis:
Based on the Alexion Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for Alexion Pharmaceuticals Inc is not available over the next 12 months. Alexion Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Alexion Pharmaceuticals Inc is Very Bullish, which is based on 2 positive signals and 0 negative signals. At the last closing, Alexion Pharmaceuticals Inc’s stock price was USD 182.50. Alexion Pharmaceuticals Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +4.36% over the last year.

About

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generaliz ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

-8.36 (-1.25%)

USD72.27B 9.28 6.88
VRTX Vertex Pharmaceuticals Incorpo..

-9.49 (-3.62%)

USD66.97B 29.06 18.23
MRNA Moderna Inc

-4.57 (-3.21%)

USD54.20B 4.82 2.41
BNTX BioNTech SE

-2.74 (-1.71%)

USD36.74B 3.67 1.75
RPRX Royalty Pharma plc

-0.85 (-2.06%)

USD27.88B 27.76 15.36
SGEN Seagen Inc

-3.55 (-2.42%)

USD26.98B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

-0.81 (-2.66%)

USD19.31B 46.16 5.06
INCY Incyte Corporation

-2.12 (-2.81%)

USD16.73B 17.68 22.08
ARGX argenx SE

-11.20 (-3.55%)

USD16.53B N/A N/A

ETFs Containing ALXN

Symbol Name Weight Mer Price(Change) Market Cap
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+1.58 (+5.53%)

USD8.57M
LABD Direxion Daily S&P Biotec.. 0.00 % 1.07 %

+7.79 (+14.80%)

USD0.07B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.49 %

+0.04 (+0.41%)

USD0.04B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.04 (-0.71%)

USD0.46B
ETLI:XETRA Legal & General UCITS ETF.. 0.00 % 0.49 %

-0.06 (-0.62%)

USD0.04B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 4.01% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.01% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 60.31% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.31% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 14.25% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.25% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.08% N/A N/A N/A N/A
Risk Adjusted Return 47.38% N/A N/A N/A N/A
Market Capitalization 40.34B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 59.23 N/A N/A N/A N/A
Price/Book Ratio 3.25 N/A N/A N/A N/A
Price / Cash Flow Ratio 13.43 N/A N/A N/A N/A
EV/EBITDA 42.56 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 4.43% N/A N/A N/A N/A
Return on Invested Capital 20.68% N/A N/A N/A N/A
Return on Assets 10.08% N/A N/A N/A N/A
Debt to Equity Ratio 20.77% N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.36 N/A N/A N/A N/A
Short Percent 4.44% N/A N/A N/A N/A
Beta 1.26 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike